General
Preferred name
Daptomycin
Synonyms
LY146032 ()
Dapcin ()
Cidecin ()
LY-164032 ()
Daptomycine ()
Cubicin ()
Daptomycin hospira ()
Daptomicina ()
Dapzura rt ()
LY 146032 ()
Cubicin rf ()
LY-146032 ()
P&D ID
PD071738
CAS
103060-53-3
Tags
available
drug
Drug indication
osteomyelitis
Bacterial infection
Drug Status
approved
Max Phase
4.0
First approval
2003
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Daptomycin is a 13 member amino acid cyclic lipopeptide antibiotic active against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant Enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci and corynebacteria. Daptomycin is derived from the fermentation product of Streptomyces roseosporus. ;
MOA Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. The binding and integration of daptomycin into the cell membrane is calcium dependent. Calcium ions cause a conformational change in daptomycin, augmenting its amphipathicity (hydrophilic head group and hydrophobic tail group), leading to incorporation into the cell membrane.; This binding causes rapid depolarisation, resulting in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death. The bactericidal activity of daptomycin is concentration-dependent. There is in vitro evidence of synergy with β-lactam antibiotics.;
DESCRIPTION Daptomycin is a semi-synthetic cyclic lipopeptide antibacterial with broad-spectrum activity against Gram-positive bacteria. It is a bacterial metabolite that was isolated from Streptomyces roseosporus. Daptomycin rapidly depolarizes the bacterial cell membrane which disrupts DNA, RNA and protein synthesis and results in cell death.
This antibacterial was removed from the World Health Organization's List of Essential Medicines in 2019. (GtoPdb)
DESCRIPTION Daptomycin (LY146032) is a cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
7
AdooQ Bioactive Compound Library
A10289
ChEMBL Approved Drugs
CHEMBL387675
ChEMBL Drugs
CHEMBL387675
DrugMAP
DMKDU16
DrugMAP Approved Drugs
DMKDU16
Guide to Pharmacology
10904
TargetMol Bioactive Compound Library
T1665
External IDs
28
Properties
(calculated by RDKit )
Molecular Weight
1619.71
Hydrogen Bond Acceptors
24
Hydrogen Bond Donors
22
Rotatable Bonds
35
Ring Count
4
Aromatic Ring Count
3
cLogP
-5.62
TPSA
702.02
Fraction CSP3
0.53
Chiral centers
13.0
Largest ring
31.0
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
antibiotic
Bacterial
DNA synthesis
Pathway
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Microbiology/virology
Therapeutic Class
Antibiotics
Source data